MedTrace Logo

Insulin, Neurogenetics and Memory in Alzheimer's Disease

NCT00018382 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL

Last updated 2009-01-21

No results posted yet for this study

Summary

This study examines the use of insulin-sensitizing compounds, as therapeutic agents for cognitive impairment in Alzheimer's disease.

Conditions

  • Alzheimer Disease

Interventions

DRUG

rosiglitazone

Sponsors & Collaborators

Principal Investigators

  • Steven Kahn, M.D.

  • Sanjay Asthana, M.D.

  • Alfred Fujimoto, M.D.

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE

Eligibility

Min Age
55 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
1999-10-31
Completion
2003-03-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00018382 on ClinicalTrials.gov